Sodium–glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) such as empagliflozin (EMPA) are currently part of therapy for patients with heart failure (HF) due to their cardioprotective effects [7]. The gene discussed is SLC5A2; the disease is heart failure.